Peter Lindgren

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: VALUE IN HEALTH REGIONAL ISSUES. 2023;37:81-87
The Disease Burden and Economic Burden of Cancer in 9 Countries in the Middle East and Africa
Hofmarcher T; Garcia AM; Wilking N; Lindgren P
Article: NATURE REVIEWS UROLOGY. 2023;20(8):494-501
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI; MacLennan S; Ribal MJ; Roobol MJ; Dimitropoulos K; van den Broeck T; MacLennan SJ; Axelsson SE; Gandaglia G; Willemse P-P; Mastris K; Ransohoff JB; Devecseri Z; Abbott T; De Meulder B; Bjartell A; Asiimwe A; N'Dow J; PIONEER Consortium
Article: BLOOD PRESSURE MONITORING. 2023;28(2):86-95
Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics.
Willis M; Darwiche G; Carlsson M; Nilsson A; Wohlin J; Lindgren P
Article: VALUE IN HEALTH. 2023;26(4S):3-10
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study.
de Pouvourville G; Cunningham D; Fricke F-U; Lindgren P; Mantovani L; Murphy LA; Solà-Morales O; Mestre-Ferrandiz J; Akehurst R
Article: VALUE IN HEALTH. 2023;26(3):328-335
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: FRONTIERS IN MEDICINE. 2023;10:1119506
A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer
Hofmarcher T; Malmberg C; Lindgren P
Article: FRONTIERS IN NEUROLOGY. 2023;14:1175922
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Tate A; Suarez-Calvet M; Ekelund M; Eriksson S; Eriksdotter MM; Van der Flier W; Georges J; Kivipelto MG; Kramberger M; Lindgren P; Lopez JDG; Lotjonen J; Persson S; Pla S; Solomon A; Thurfjell L; Wimo A; Winblad B; Jonsson L
Article: JOURNAL OF CANCER POLICY. 2022;34:100362
Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe
Hofmarcher T; Lindgren P; Wilking N
Article: PHARMACOECONOMICS (AUCKLAND). 2022;40(11):1095-1105
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates
Di Tanna GL; Angell B; Urbich M; Lindgren P; Gaziano TA; Globe G; Stollenwerk B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(6):1059-1070
Value appropriation in hepatitis C
Lindgren P; Lofvendahl S; Bradvik G; Weiland O; Jonsson B
Article: EUROPEAN HEART JOURNAL - QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(1):31-38
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
Landmesser U; Lindgren P; Hagstrom E; Hout BV; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Article: PLOS ONE. 2022;17(12):e0278369
Motivation 2 Quit (M2Q): A cluster randomized controlled trial evaluating the effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare
Leppanen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: NEUROLOGY AND THERAPY. 2021;10(2):919-940
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Article: JOURNAL OF VIRAL HEPATITIS. 2021;28(1):142-146
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals
Lindgren P; Lofvendahl S; Bradvik G; Weiland O
Article: DIABETOLOGIA. 2020;63(12):2582-2594
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Steen Carlsson K; Jendle J
Article: BRITISH JOURNAL OF SPORTS MEDICINE. 2020;54(21):1294-1299
A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group
Journath G; Hammar N; Vikstrom M; Linnersjo A; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Article: BMC EMERGENCY MEDICINE. 2020;20(1):85
Healthcare pathways and resource use: mapping consequences of ambulance assessment for direct care with alternative healthcare providers
Varg S; Vicente V; Castren M; Lindgren P; Rehnberg C
Article: DIABETES, OBESITY AND METABOLISM. 2020;22(9):1586-1597
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden
Persson S; Johansen P; Andersson E; Lindgren P; Thielke D; Thorsted BL; Jendle J; Carlsson KS
Article: NATURE REVIEWS UROLOGY. 2020;17(6):351-362
Introducing PIONEER: a project to harness big data in prostate cancer research
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; Andersson E; Arala H; Auvinen A; Bangma C; Burke D; Cardone A; Casariego J; Cuperus G; Dabestani S; Esperto F; Fossati N; Fridhammar A; Gandaglia G; Tandefelt DG; Horn F; Huber J; Hugosson J; Huisman H; Josefsson A; Kilkku O; Kreuz M; Lardas M; Lawson J; Lefresne F; Lejeune S; Longden-Chapman E; McVie G; Moris L; Mottet N; Murtola T; Nicholls C; Pang KH; Pascoe K; Picozzi M; Plass K; Pohjanjousi P; Reaney M; Remmers S; Robinson P; Schalken J; Schravendeel M; Seisen T; Servan A; Shiranov K; Snijder R; Steinbeisser C; Taibi N; Talala K; Tilki D; Van den Broeck T; Vassilev Z; Voima O; Vradi E; Waldeck R; Weistra W; Willemse P-P; Wirth M; Wolfinger R; Kermani NZ
Article: BMJ OPEN. 2020;10(6):e032573
Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden
Keel G; Muhammad R; Savage C; Spaak J; Gonzalez I; Lindgren P; Guttmann C; Mazzocato P
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49
The cost of cancer in Europe 2018
Hofmarcher T; Lindgren P; Wilking N; Jonsson B
Article: INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT. 2019;34(4):1439-1455
Exploring staff experience of economic efficiency requirements in health care: A mixed method study
Korlen S; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: DISABILITY AND REHABILITATION. 2019;41(8):966-973
Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis
Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmuller H; Lindgren P
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(1):15-24
Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method
Landfeldt E; Zethraeus N; Lindgren P
Article: JOURNAL OF MULTIDISCIPLINARY HEALTHCARE. 2019;12:1075-1083
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic
Rafiq M; Keel G; Mazzocato P; Spaak J; Guttmann C; Lindgren P; Savage C
Article: BMC HEALTH SERVICES RESEARCH. 2018;18(1):963
The development and validation of a scale to explore staff experience of governance of economic efficiency and quality (GOV-EQ) of health care
Korlen S; Richter A; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: AIDS CARE. 2018;30(9):1090-1098
Excess costs of non-infectious comorbidities among people living with HIV - estimates from Denmark and Sweden
Hjalte F; Calara PS; Blaxhult A; Helleberg M; Wallace K; Lindgren P
Article: MUSCLE AND NERVE. 2018;58(3):367-373
Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis
Landfeldt E; Mayhew A; Straub V; Lochmueller H; Bushby K; Lindgren P
Article: DIABETES/METABOLISM RESEARCH AND REVIEWS. 2018;34(4):e2984
Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden
Julin B; Willers C; Leksell J; Lindgren P; Muth KL; Svensson A-M; Lilja M; Dahlstrom T
Article: PLOS ONE. 2018;13(6):e0199170
Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study
Willers C; Iderberg H; Axelsen M; Dahlstrom T; Julin B; Leksell J; Lindberg A; Lindgren P; Muth KL; Svensson A-M; Lilja M
Article: JAMA CARDIOLOGY. 2017;2(10):1069-1078
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
Article: HEALTH SERVICES MANAGEMENT RESEARCH. 2017;30(3):148-155
Professionals' perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement.
Korlén S; Amer-Wåhlin I; Lindgren P; von Thiele Schwarz U
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2017;96(5):597-606
Case mix adjusted variation in cesarean section rate in Sweden
Mesterton J; Ladfors L; Abreu AE; Lindgren P; Saltvedt S; Weichselbraun M; Amer-Wahlin I
Article: JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT. 2017;31(2):126-141
Managerial strategies to make incentives meaningful and motivating
Korlen S; Essen A; Lindgren P; Amer-Wahlin I; Schwarz UVT
Article: CLINICAL THERAPEUTICS. 2017;39(4):771-786.e3
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; van Hout B
Article: PHARMACOECONOMICS (AUCKLAND). 2017;35(2):249-258
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
Landfeldt E; Alfredsson L; Straub V; Lochmuller H; Bushby K; Lindgren P
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170
The cost and burden of cancer in the European Union 1995-2014
Jonsson B; Hofmarcher T; Lindgren P; Wilking N
Article: JMIR RESEARCH PROTOCOLS. 2016;5(3):e188
A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study.
Leppänen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: CLINICAL CARDIOLOGY. 2016;39(6):313-320
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Article: BMC PREGNANCY AND CHILDBIRTH. 2016;16(1):125
Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study
Mesterton J; Lindgren P; Abreu AE; Ladfors L; Lilja M; Saltvedt S; Amer-Wahlin I
Article: JOURNAL OF NEUROLOGY. 2016;263(5):906-915
Quantifying the burden of caregiving in Duchenne muscular dystrophy
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmuller H; Bushby K
Article: DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY. 2016;58(5):508-515
Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: NEUROMUSCULAR DISORDERS. 2015;25(12):937-944
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: VALUE IN HEALTH. 2015;18(4):439-448
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
Berg J; Lindgren P; Mejhert M; Edner M; Dahlstrom U; Kahan T
Article: JOURNAL OF NEUROMUSCULAR DISEASES. 2015;2(1):63-72
Compliance to Care Guidelines for Duchenne Muscular Dystrophy.
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: PLOS ONE. 2015;10(11):e0140201
Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden
Journath G; Hammar N; Elofsson S; Linnersjo A; Vikstrom M; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Article: NEUROLOGY. 2014;83(6):529-536
The burden of Duchenne muscular dystrophy An international, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: THROMBOSIS RESEARCH. 2014;133(2):162-167
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesna P; Mesterton J; Lindgren P
Article: JRSM CARDIOVASCULAR DISEASE. 2014;3:2048004014548735
Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure.
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2013;29(10):1249-1255
Cost-Effectiveness of Dronedarone in Patients With Atrial Fibrillation in the ATHENA Trial
Berg J; Sauriol L; Connolly S; Lindgren P
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(3):481-493
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland
Nilsson J; Akerborg O; Bego-Le Bagousse G; Rosenquist M; Lindgren P
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2013;24(3):260-265
Long term health care consumption and cost expenditure in systolic heart failure
Mejhert M; Lindgren P; Schill O; Edner M; Persson H; Kahan T
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(4):445-450
Cost-effectiveness of statins revisited: lessons learned about the value of innovation
Lindgren P; Jonsson B
Article: CLINICAL THERAPEUTICS. 2012;34(8):1788-1802
Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland
Akerborg O; Nilsson J; Bascle S; Lindgren P; Reynolds M
Article: PHARMACOECONOMICS (AUCKLAND). 2012;30(6):513-530
Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Article: THROMBOSIS RESEARCH. 2012;129(5):e233-e237
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
Salaj P; Penka M; Smejkal P; Geierova V; Ovesna P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2011;124(3):214-225
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
Kasteng F; Eriksson J; Sennfalt K; Lindgren P
Article: EUROPACE. 2011;13(1):23-30
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries
Holstenson E; Ringborg A; Lindgren P; Coste F; Diamand F; Nieuwlaat R; Crijns H
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2010;64(9):1228-1234
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial
Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETES AND METABOLISM. 2010;36(3):198-203
Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes
Ringborg A; Lindgren P; Yin DD; Martinell M; Stalhammar J
Article: HAEMOPHILIA. 2010;16(3):487-494
The value of early treatment in patients with haemophilia and inhibitors
Kavakli K; Yesilipek A; Antmen B; Aksu S; Balkan C; Yilmaz D; Kupesiz A; Sasmaz I; Lindgren P; Mesterton J
Article: QUALITY OF LIFE RESEARCH. 2010;19(3):381-390
Factors determining utility measured with the EQ-5D in patients with atrial fibrillation
Berg J; Lindgren P; Nieuwlaat R; Bouin O; Crijns H
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;38(6):409-418
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G; Lindgren P; Geborek P
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2009;25(11):e362-e369
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Joensson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(5):576-582
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden
Ringborg A; Yin DD; Martinell M; Stalhammar J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2009;63(7):997-1007
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)
Ringborg A; Cropet C; Jonsson B; Gagliardino JJ; Ramachandran A; Lindgren P
Article: ATHEROSCLEROSIS SUPPLEMENTS. 2009;10(1):3-21
Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008
Atella V; Brady A; Catapano AL; Critchley J; Graham IM; Hobbs FDR; Leal J; Lindgren P; Vanuzzo D; Volpe M; Wood D; Paoletti R
Article: MULTIPLE SCLEROSIS JOURNAL. 2009;15(6):741-751
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions
Kobelt G; Texier-Richard B; Lindgren P
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2009;25(2):181-189
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Lindgren P; Geborek P; Kobelt G
Article: ALLERGY. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2009;64(3):431-438
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
Price D; Berg J; Lindgren P
Article: PHARMACOECONOMICS (AUCKLAND). 2009;27(3):221-230
The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone Results from ASCOT
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETIC MEDICINE. 2008;25(10):1178-1186
Prevalence and incidence of Type 2 diabetes and its complications 1996-2003 -: estimates from a Swedish population-based study
Ringborg A; Lindgren P; Martinell M; Yin DD; Schon S; Stalhammar J
Article: MULTIPLE SCLEROSIS JOURNAL. 2008;14(5):679-690
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2008;62(5):708-716
Resource use and costs of type 2 diabetes in Sweden -: estimates from population-based register data
Ringborg A; Martinell M; Stalhammar J; Yin DD; Lindgren P
Article: JOURNAL OF CARDIOVASCULAR RISK. 2008;15(2):230-233
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader E-L; Jonsson B
Article: EUROPACE. 2008;10(4):403-411
Costs of atrial fibrillation in five European countries:: results from the Euro Heart Survey on atrial fibrillation
Ringborg A; Nieuwlaat R; Lindgren P; Joensson B; Fidan D; Maggioni AP; Lopez-Sendon J; Stepinska J; Cokkinos DV; Crijns HJGM
Article: RESPIRATORY MEDICINE. 2008;102(2):219-231
Economic evaluation of FE_NO measurement in diagnosis and 1-year management of asthma in Germany
Berg J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Article: CLINICAL THERAPEUTICS. 2007;29(6):1184-1202
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: A European model based on the CLARITY and COMMIT trials
Berg J; Lindgren P; Spiesser J; Parry D; Jonsson B
Article: EUROPEAN HEART JOURNAL. 2007;28(12):1448-1453
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jonsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):51-57
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
Brueggenjuergen B; Lindgren P; Ehlken B; Rupprecht H-J; Willich SN
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):25-30
Utility loss and indirect costs following cardiovascular events in hypertensive patients:: the ASCOT health economic substudy
Lindgren P; Kahan T; Poulter N; Buxton M; Svarvar P; Dahlof B; Jonsson B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2007;23(2):177-183
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective
Lindgren P; Lindstrom J; Tuomilehto J; Uusitupa M; Peltonen M; Jonsson B; de Faire U; Hellenius M-L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:5-13
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
Kobelt G; Berg J; Lindgren P; Jönsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:55-64
Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:75-85
Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:96-104
Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:65-74
Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA; Associación Española de Esclerosis Múltiple
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:14-23
Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:86-95
Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:34-44
Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:45-54
Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2006;77(8):918-926
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jonsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(4):354-362
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Ringborg A; Lindgren P; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DDP; Jönsson L
Article: RHEUMATOLOGY. 2005;44(9):1169-1175
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(8):1174-1179
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
Kobelt G; Lindgren P; Singh A; Klareskog L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:68-73
Cost of Parkinson's disease in Europe
Lindgren P; von Campenhausen S; Spottke E; Siebert U; Dodel R
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(1):29-36
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events:: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B
Article: CLINICAL THERAPEUTICS. 2005;27(1):100-110
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2004;11(6):460-465
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study
Lamy A; Jönsson B; Weintraub WS; Zhao F; Chrolavicius S; Bakhai A; Culler S; Gafni A; Lindgren P; Mahoney E; Yusuf S
Article: JOURNAL OF INTERNAL MEDICINE. 2004;255(5):562-570
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden:: a long-term model based on the cure trial
Lindgren P; Jönsson B; Yusuf S
Article: PREVENTIVE MEDICINE. 2003;36(4):403-409
Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm -: a stochastic model of exercise and dietary advice
Lindgren P; Fahlstadius P; Hellenius ML; Jönsson B; de Faire U
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):37-42
The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden.
Lindgren P; Jönsson B; Duchane J
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319
Modeling the progression of rheumatoid arthritis -: A two-country model to estimate costs and consequences of rheumatoid arthritis
Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Article: PHARMACOECONOMICS (AUCKLAND). 2002;20(2):101-108
Cost-effectiveness analysis of exemestane compared with Megestrol in advanced breast cancer -: A model for Europe and Australia
Lindgren P; Jönsson B; Redaelli A; Radice D
Article: PHARMACOECONOMICS (AUCKLAND). 1999;16(4):409-416
Costs of mini mental state examination-related cognitive impairment
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease:: A Markov model
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Visa fler

Alla övriga publikationer

Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;80:55-69
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
Solmi M; Croatto G; Fornaro M; Schneider LK; Rohani-Montez SC; Fairley L; Smith N; Bitter I; Gorwood P; Taipale H; Tiihonen J; Cortese S; Dragiotiu E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Boyer L; De Prisco M; Vieta E; Correll CU
Letter: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2023;24(3):483
Reply to: making the rules make sense: valuation of constrained resources
Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(8):1259-1261
Breaking the rules: decision-making under absolute resource constraints
Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2021;22(6):851-854
Something borrowed, something new: measuring hospital performance in the context of value based health care
Lindgren P; Althin R
Review: HEALTH POLICY. 2020;124(4):404-410
Risk sharing in managed entry agreements-A review of the Swedish experience
Andersson E; Svensson J; Persson U; Lindgren P
Published conference paper: JAMA CARDIOLOGY. 2019;4(7):691-695
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Letter: ORPHANET JOURNAL OF RARE DISEASES. 2019;14(1):75
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
Landfeldt E; Lochmueller H; Lindgren P
Letter: NEUROMUSCULAR DISORDERS. 2018;28(1):100
Compliance to care guidelines for Duchenne muscular dystrophy in Italy
Landfeldt E; Lindgren P; Guglieri M; Lochmuller H; Bushby K
Review: JOURNAL OF NEUROMUSCULAR DISEASES. 2017;4(4):285-292
Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review.
Landfeldt E; Edström J; Lindgren P; Lochmüller H
Review: PHARMACOECONOMICS (AUCKLAND). 2017;35(3):297-318
A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
Wei C-Y; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
Corrigendum: NEUROMUSCULAR DISORDERS. 2016;26(4-5):329
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT) (vol 25, pg 937, 2015)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmiiller H; Bushby K
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A558
DETERMINISTIC VERSUS STOCHASTIC PREDICTION OF RISK FOR CARDIOVASCULAR EVENTS
Villa G; Lothgren M; Gandra SR; Lindgren P; van Hout B
Meeting abstract: VALUE IN HEALTH. 2010;13(3):A58
RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES
Pettersson B; Lindgren P; Ringborg A; Martinell M; Stalhammar J
Meeting abstract: VALUE IN HEALTH. 2009;12(7):A335
DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES
Akerborg O; Bascle S; Lindgren P
Review: VALUE IN HEALTH. 2009;12(6):857-871
Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model
Schwander B; Gradl B; Zoellner Y; Lindgren P; Diener H-C; Lueders S; Schrader J; Antonanzas Villar F; Greiner W; Jonsson B
Review: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(2):138-143
From 4S to IDEAL: the health economics of the statin trials
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A548
COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
Kobelt G; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A410
FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION
Berg J; Lindgren P; Nieuwlaat R; Bascle S; Crijns H
Published conference paper: CURRENT MEDICAL RESEARCH AND OPINION. 2008;24(7):2089-2101
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials
Berg J; Fidan D; Lindgren P
Editorial comment: HEART. 2008;94(2):e4
Economic evaluation of ASCOT-BPLA:: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Corrigendum: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(4):359
Costs and quality of life in multiple sclerosis in The Netherlands (vol 7, pg S55, 2006)
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):197-198
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the IDEAL trial
Lindgren P; Jonsson B
Review: EUROPEAN HEART JOURNAL, SUPPLEMENT. 2007;9(C):C3-C74
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A64
Determination of health care costs incurred by swedish patients with type 2 diabetes
Ringborg A; Stalhammar J; Martinell D; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A110
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the US
Berg J; Lindgren P
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A353
Cost-utility analysis of eprosartan compared to enalapril and ramipril in the treatment of moderate to severe hypertension in Sweden
Lindgren P; Schwander B; Zollner Y; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A346-A347
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: European model results based on clarity and commit
Berg J; Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A333
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in Germany
Berg J; Lindgren P; Joensson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A330
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader EL; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231-A232
Cost of inpatient and outpatient care of Swedish patients with diabetes mellitus
Ringborg A; Berwick S; Stalhammar J; Martinell M; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231
Cost of a major hypoglycaemic event in type 1 and type 2 diabetic patients - A systematic literature review
Lilja U; Asmussen M; Lindgren P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):178
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(6):A134
The cost of multiple sclerosis (MS) in Europe
Berg J; Kobelt G; Lindgren P; Fredrikson S; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(3):253
9301 cost-effectiveness of long-term therapy with clopidogrel following percutaneous coronary intervention:: A Swedish analysis of the CREDO-trial
Ringborg A; Lindgren P; Jönsson B
Thesis / dissertation: 2005
Modeling the economics of prevention
Lindgren, Peter
Meeting abstract: VALUE IN HEALTH. 2004;7(6):694
Cost-effectiveness of reduction in cardiovascular outcomes with atorvastatin in patients with normal to mildly elevated cholesterol levels, treated for hypertension:: The ASCOT-LLA study
Lindgren P; Buxton MJ; Kahan T; Poulter N; Dahlöf B; Sever P; Wedel H; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2004;7(6):688
The cost-effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention in Sweden:: An analysis of PCI-cure
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Review: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S63-S66
Economic evidence in Parkinson's disease: a review.
Lindgren P
Meeting abstract: VALUE IN HEALTH. 2003;6(6):621
Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST segment elevation (ACS) in Scandinavian countries
Lindgren P; Jönsson B; Spiesser J; Carita P; Gabriel S
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:586
Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Carita P
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:245
Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Spiesser J
Visa fler

Anställningar

Adjungerad Professor, Lärande, Informatik, Management och Etik, Karolinska Institutet, 2021-2025

Examina och utbildning

Docent, Hälsoekonomi, Karolinska Institutet, 2014
MEDICINE DOKTORSEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 2005

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI